| Literature DB >> 33669136 |
Rouven Berndt1,2, Martin Albrecht3, René Rusch1,2.
Abstract
The transplantation of various immune cell types are promising approaches for the treatment of ischemic cardiovascular disease including myocardial infarction (MI) and peripheral arterial disease (PAD). Major limitation of these so-called Advanced Therapy Medicinal Products (ATMPs) is the ischemic microenvironment affecting cell homeostasis and limiting the demanded effect of the transplanted cell products. Accordingly, different clinical and experimental strategies have been evolved to overcome these obstacles. Here, we give a short review of the different experimental and clinical strategies to solve these issues due to ischemic cardiovascular disease.Entities:
Keywords: Advanced Therapy Medicinal Product (ATMP); Ischemia/Reperfusion (I/R); Myocardial Infarction (MI); Peripheral Arterial Disease (PAD); cardiovascular disease; cell therapy
Mesh：
Substances：
Year: 2021 PMID： 33669136 PMCID： PMC7956787 DOI： 10.3390/ijms22052312
Source DB: PubMed Journal: Int J Mol Sci ISSN： 1422-0067 Impact factor: 5.923